EUVIMEDEUVIMED entdecken
FallberichtOpen Access

Infantile fibrosarcoma–like tumor driven by novel RBPMS-MET fusion consolidated with cabozantinib

Ajay Gupta iD, Jennifer A Belsky, Kathleen M Schieffer, Kristen Leraas, Elizabeth Varga, Sean D McGrath, Selene C Koo, Vincent Magrini, Richard K Wilson, Peter White iD, Elaine R Mardis, Kris R Jatana und 2 weitere

Molecular Case Studies · 2020-10 · 6 (5) · a005645

DOI: 10.1101/mcs.a005645 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Molecular Case Studies, online erschienen am 07.10.2020. Verfasst von Ajay Gupta und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Oncology, Blood and Marrow Transplant, Nationwide Children's Hospital, Columbus, Ohio 43205, USA. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Infantile fibrosarcoma (IFS) is nearly universally driven by gene fusions involving the NTRK family. ETV6-NTRK3 fusions account for ∼85% of alterations; the remainder are attributed to NTRK-variant fusions. Rarely, other genomic aberrations have been described in association with tumors identified as IFS or IFS-like. We describe the utility of genomic characterization of an IFS-like tumor. We also describe the successful treatment combination of VAC (vincristine, actinomycin, cyclophosphamide) with tyrosine kinase inhibitor (TKI) maintenance in this entity. This patient presented at birth with a right facial mass, enlarging at 1 mo to 4.9 × 4.5 × 6.3 cm. Biopsy demonstrated hypercellular fascicles of spindle cells with patchy positivity for smooth muscle actin (SMA) and negativity for S100, desmin, myogenin, and MyoD1. Targeted RNA sequencing identified a novel RBPMS-MET fusion with confirmed absence of ETV6-NTRK3 , and the patient was diagnosed with an IFS-like tumor. A positron emission tomography (PET) scan was negative for metastatic disease. VAC was given for a duration of 10 mo. Resection at 13 mo of age demonstrated positive margins. Cabozantinib, a MET-targeting TKI, was initiated. The patient tolerated cabozantinib well and has no evidence of disease at 24 mo of age. We describe a novel RBPMS-MET driver fusion in association with a locally aggressive IFS-like tumor. MET functions as an oncogene and, when associated with the RNA binding protein RBPMS, forms an in-frame fusion product that retains the MET kinase domain. This fusion is associated with aberrant cell signaling pathway expression and subsequent malignancy. We describe treatment with cabozantinib in a patient with an IFS-like neoplasm.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnilidesBiomarkers, TumorFibrosarcomaGene FusionHumansInfantOncogene Proteins, FusionOncogenesProtein Kinase InhibitorsProto-Oncogene Proteins c-etsProto-Oncogene Proteins c-metPyridinesRNA-Binding ProteinsRepressor Proteins

Stichwörter der Autor:innen

facial neoplasm

Substanzen

AnilidesBiomarkers, TumorOncogene Proteins, FusionProtein Kinase InhibitorsProto-Oncogene Proteins c-etsPyridinesRBPMS protein, humanRNA-Binding ProteinsRepressor Proteinscabozantinib

Autor:innen und Institutionen

  • Division of Hematology, Oncology, Blood and Marrow Transplant, Nationwide Children's Hospital, Columbus, Ohio 43205, USA.
  • The Steve and Cindy Rasmussen Institute for Genomic Medicine, Nationwide Children's Hospital, Columbus, Ohio 43205, USA.
  • Department of Pathology, Nationwide Children's Hospital, Columbus, Ohio 43205, USA.
  • Department of Pathology, The Ohio State University, Columbus, Ohio 43210, USA.
  • Department of Pediatrics, The Ohio State University, Columbus, Ohio 43210, USA.
  • Department of Otolaryngology, Nationwide Children's Hospital, Columbus, Ohio 43205, USA.

ORCID-Profile: Ajay Gupta, Peter White

Zitieren

APA

Gupta, A., Belsky, J. A., Schieffer, K. M., Leraas, K., Varga, E., McGrath, S. D., Koo, S. C., Magrini, V., Wilson, R. K., White, P., Mardis, E. R., Jatana, K. R., Cottrell, C. E., & Setty, B. A. (2020). Infantile fibrosarcoma–like tumor driven by novel RBPMS-MET fusion consolidated with cabozantinib. Molecular Case Studies, 6(5), a005645. https://doi.org/10.1101/mcs.a005645

Vancouver

Gupta A, Belsky JA, Schieffer KM, Leraas K, Varga E, McGrath SD, et al. Infantile fibrosarcoma–like tumor driven by novel RBPMS-MET fusion consolidated with cabozantinib. Molecular Case Studies. 2020;6(5):a005645. doi:10.1101/mcs.a005645

BibTeX
@article{Gupta2020,
  author = {Gupta, Ajay and Belsky, Jennifer A and Schieffer, Kathleen M and Leraas, Kristen and Varga, Elizabeth and McGrath, Sean D and Koo, Selene C and Magrini, Vincent and Wilson, Richard K and White, Peter and Mardis, Elaine R and Jatana, Kris R and Cottrell, Catherine E and Setty, Bhuvana A},
  title = {Infantile fibrosarcoma–like tumor driven by novel RBPMS-MET fusion consolidated with cabozantinib},
  journal = {Molecular Case Studies},
  year = {2020},
  volume = {6},
  number = {5},
  pages = {a005645},
  doi = {10.1101/mcs.a005645}
}
Kostenlos starten →